Ticker

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in Immunotherapy-Resistant MSS/pMMR Colorectal Cancer SYDNEY,…

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from t

Completion Removes the Remaining Conversion Overhang Associated With the Company's Convertible Note Financing and, Management Believes, Enhances Financial and Strategic Flexibility MONTEREY PARK, CA / ACCESS Newswire / August 26, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a U.S.-based specialty grocery retailer and emerging platform for technology-enabled business initiatives,…

MONTEREY PARK, CA / ACCESS Newswire / August 25, 2026 / Maison Solutions Inc. (Nasdaq:MSS) (the "Company") today announced that, on August 20, 2026, it received a notification letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company had not timely filed its Annual Report on Form 10-K for the fiscal year ended April 30, 2026 (the "Form 10-K"), it is not…

ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform" PR Newsw